Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Merck discontinues development of 2 late-stage cancer assets
Merck is ending development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, both of which are in phase 3 development.
Gabrielle Masson
Dec 16, 2024 5:39pm
iTeos drops one of 3 clinical assets from pipeline
Dec 12, 2024 3:10pm
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 9:07am
AstraZeneca, Daiichi share data behind Dato-DXd do-over
Dec 6, 2024 5:21am
Roche's TIGIT prospect fails another phase 3 lung cancer test
Nov 26, 2024 4:11am
AstraZeneca, Daiichi pull lung cancer BLA for Enhertu follow-up
Nov 12, 2024 5:27am
